Big pharma, AstraZeneca and the Broad Institute in Cambridge, Massachusetts announced a pharma partners collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs.
Under the two-year pharma partners collaboration announced , the two organizations will work together to address this challenge by bringing together deep expertise in bacterial genomics and biochemistry with a unique collection of chemical compounds and chemical screening capabilities.
Under this pharma partners agreement, screening and hit-to-lead chemistry will take place in the Broad's Chemical Biology Platform and AstraZeneca will optimize, develop and commercialize potential compounds from identified, high-quality leads
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with AstraZeneca
Related reports: Infectives Partnering Terms and Agreements
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity